Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.10 USD
Change Today -0.26 / -1.50%
Volume 746.2K
ELGX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

endologix inc (ELGX) Snapshot

Open
$17.35
Previous Close
$17.36
Day High
$17.43
Day Low
$16.94
52 Week High
04/6/15 - $18.07
52 Week Low
09/29/14 - $10.29
Market Cap
1.2B
Average Volume 10 Days
414.8K
EPS TTM
$-0.64
Shares Outstanding
67.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDOLOGIX INC (ELGX)

Related News

No related news articles were found.

endologix inc (ELGX) Related Businessweek News

No Related Businessweek News Found

endologix inc (ELGX) Details

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular repair (EVAR) products, including EVAR stent graft and catheter delivery system under the brand names Powerlink, IntuiTrak, AFX, and VELA Proximal Endograft. It also provides endovascular sealing (EVAS) product that is based on the Nellix platform to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patient’s anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths. It sells its products through direct sales force, network of agents, and independent distributors. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

590 Employees
Last Reported Date: 03/2/15
Founded in 1992

endologix inc (ELGX) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $930.9K
President
Total Annual Compensation: $580.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $425.5K
Vice President of Human Resources
Total Annual Compensation: $169.5K
Vice President of Quality
Total Annual Compensation: $346.1K
Compensation as of Fiscal Year 2014.

endologix inc (ELGX) Key Developments

Endologix Inc. Announces Resignation of Shelley Thunen as Chief Financial Officer

Endologix Inc. announced that Shelley Thunen, Chief Financial Officer, has decided to resign from her position in order to spend more time with family and pursue other personal interests. Ms. Thunen will continue to serve as the company's Chief Financial Officer through the recruitment and transition process to a new CFO and will remain available to the company as long as required to ensure a smooth and complete transition.

Endologix Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year of 2015; Provides Earnings Guidance for the First Quarter of 2015

Endologix Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $38,847,000 compared to $35,249,000 a year ago. Loss from operations was $11,130,000 compared to $1,140,000 a year ago. Net loss before income tax expense was $14,633,000 compared to $3,790,000 a year ago. Net loss was $14,782,000 or $0.22 per basic and diluted share compared to $3,412,000 or $0.05 per basic and diluted share a year ago. Adjusted net loss was $7,211,000 or $0.11 per share compared to $757,000 or $0.01 per share a year ago. Adjusted EBITDA was $3,418,000 or $0.05 per share compared to $1,305,000 or $0.02 per share a year ago. Capital expenditures were approximately $3.2 million. For the year, the company reported total revenue of $147,588,000 compared to $99,507,000 a year ago. Loss from operations was $29,146,000 compared to $10,368,000 a year ago. Net loss before income tax expense was $32,480,000 compared to $16,078,000 a year ago. Net loss was $32,418,000 or $0.50 per basic and diluted share compared to $16,068,000 or $0.26 per basic and diluted share a year ago. Adjusted net loss was $24,764,000 or $0.38 per share compared to $7,126,000 or $0.11 per share a year ago. Adjusted EBITDA was $13,676,000 or $0.21 per share compared to $3,137,000 or $0.05 per share a year ago. The company anticipates 2015 constant currency revenue to be in the range of $163 million to $168 million, representing constant currency growth of 10% to 14% from 2014, and reported revenue in the range of $159 million to $165 million, or growth of 8% to 12% from 2014, based on the current foreign currency exchange rates. The company anticipates GAAP loss per share of $0.64 to $0.69 per share and an adjusted loss per share of $0.51 to $0.56 per share. The company expects gross margins to be about 70% or 71% on a constant currency basis as compared to 72% achieved in 2014. The anticipated decrease in gross margins is primarily the result of products and geography mix. The company expects first quarter 2015 constant currency worldwide revenue to be up about 16% to 17% over the first quarter of 2014 but nominal sequential growth. With the euro currency adjustment, the company expects the first quarter to be around $37 million to $38 million.

Endologix Inc. Presents at 27th Annual ROTH Conference, Mar-09-2015 11:00 AM

Endologix Inc. Presents at 27th Annual ROTH Conference, Mar-09-2015 11:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: John McDermott, Chairman of the Board and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELGX:US $17.10 USD -0.26

ELGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $16.74 USD +0.14
CryoLife Inc $10.15 USD +0.24
LeMaitre Vascular Inc $8.58 USD +0.07
Spectranetics Corp/The $34.85 USD +0.13
TriVascular Technologies Inc $8.89 USD -0.24
View Industry Companies
 

Industry Analysis

ELGX

Industry Average

Valuation ELGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.9x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDOLOGIX INC, please visit www.endologix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.